# Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
Canonical URL: https://biopharmsignal.com/news/CLSD/clearside-biomedical-to-pursue-strategic-sale-of-its-business-through-voluntary-chapter-11-process
Ticker: CLSD
Company: Clearside Biomedical
Source: Clearside Biomedical
Published: 2025-11-24 12:05 EST
Original Source URL: https://ir.clearsidebio.com
## Summary

- Intended to Maximize Stakeholder Value Through Structured Process - - Validated SCS Microinjector ® Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential - - CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet

## Article Body
- Intended to Maximize Stakeholder Value Through Structured Process - - Validated SCS Microinjector ® Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential - - CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet
## Recent Company News
- 2025-11-24 12:05 EST — [Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process](https://biopharmsignal.com/news/CLSD/clearside-biomedical-to-pursue-strategic-sale-of-its-business-through-voluntary-chapter-11-process) — Source: Clearside Biomedical
- 2025-08-26 12:05 EST — [Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress](https://biopharmsignal.com/news/CLSD/clearside-biomedical-announces-multiple-presentations-on-suprachoroidal-delivery-to-be-featured-at-the-25th-euretina-congress) — Source: Clearside Biomedical
- 2025-07-23 11:05 EST — [Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada](https://biopharmsignal.com/news/CLSD/clearside-biomedical-announces-approval-of-xiperer-suprachoroidal-treatment-for-uveitic-macular-edema-in-canada) — Source: Clearside Biomedical
- 2025-07-17 11:05 EST — [Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline](https://biopharmsignal.com/news/CLSD/clearside-biomedical-announces-plan-to-explore-strategic-alternatives-to-advance-its-proprietary-suprachoroidal-space-scsr-delivery-platform-and-promising-ophthalmology-pipeline) — Source: Clearside Biomedical
- 2025-06-17 11:05 EST — [Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting](https://biopharmsignal.com/news/CLSD/clearside-biomedical-announces-multiple-presentations-to-be-featured-at-the-clinical-trials-at-the-summit-meeting) — Source: Clearside Biomedical
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)